JP2017530960A5 - - Google Patents

Download PDF

Info

Publication number: JP2017530960A5
Authority: JP; Japan
Prior art keywords: carboxamide; cyano; pyrrolidine; thiazol; imidazol
Prior art date: 2015-09-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2017514705A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017530960A (ja

JP6549703B2 (ja

Filing date

2015-09-22

Publication date

2018-11-08

2014-09-23 Priority claimed from GBGB1416754.8A external-priority patent/GB201416754D0/en

2015-09-22 Application filed filed Critical

2017-10-19 Publication of JP2017530960A publication Critical patent/JP2017530960A/ja

2018-11-08 Publication of JP2017530960A5 publication Critical patent/JP2017530960A5/ja

2019-06-27 Priority to JP2019119342A priority Critical patent/JP6959299B2/ja

2019-07-24 Application granted granted Critical

2019-07-24 Publication of JP6549703B2 publication Critical patent/JP6549703B2/ja

Status Active legal-status Critical Current

2035-09-22 Anticipated expiration legal-status Critical

Links

-1 cyano, amino Chemical group 0.000 claims 24
150000001875 compounds Chemical class 0.000 claims 23
125000000217 alkyl group Chemical group 0.000 claims 21
125000001072 heteroaryl group Chemical group 0.000 claims 18
125000003545 alkoxy group Chemical group 0.000 claims 14
125000003118 aryl group Chemical group 0.000 claims 13
125000000753 cycloalkyl group Chemical group 0.000 claims 13
125000001424 substituent group Chemical group 0.000 claims 9
125000004093 cyano group Chemical group *C#N 0.000 claims 8
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 8
125000005843 halogen group Chemical group 0.000 claims 8
125000004043 oxo group Chemical group O=* 0.000 claims 8
125000000623 heterocyclic group Chemical group 0.000 claims 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
229910052739 hydrogen Inorganic materials 0.000 claims 6
150000002431 hydrogen Chemical class 0.000 claims 6
239000001257 hydrogen Substances 0.000 claims 6
125000005647 linker group Chemical group 0.000 claims 6
150000003839 salts Chemical class 0.000 claims 6
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 5
229910052805 deuterium Inorganic materials 0.000 claims 5
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 5
125000004442 acylamino group Chemical group 0.000 claims 4
125000004450 alkenylene group Chemical group 0.000 claims 4
125000002947 alkylene group Chemical group 0.000 claims 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
125000001188 haloalkyl group Chemical group 0.000 claims 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
229910052760 oxygen Inorganic materials 0.000 claims 4
239000001301 oxygen Substances 0.000 claims 4
KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 claims 3
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 3
125000005529 alkyleneoxy group Chemical group 0.000 claims 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
125000004438 haloalkoxy group Chemical group 0.000 claims 3
229910052736 halogen Inorganic materials 0.000 claims 3
150000002367 halogens Chemical class 0.000 claims 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
125000004076 pyridyl group Chemical group 0.000 claims 3
125000000714 pyrimidinyl group Chemical group 0.000 claims 3
IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 claims 3
125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
125000006323 alkenyl amino group Chemical group 0.000 claims 2
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
125000003282 alkyl amino group Chemical group 0.000 claims 2
125000000304 alkynyl group Chemical group 0.000 claims 2
125000004429 atom Chemical group 0.000 claims 2
125000001153 fluoro group Chemical group F* 0.000 claims 2
125000001183 hydrocarbyl group Chemical group 0.000 claims 2
125000002883 imidazolyl group Chemical group 0.000 claims 2
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
125000000842 isoxazolyl group Chemical group 0.000 claims 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
125000003373 pyrazinyl group Chemical group 0.000 claims 2
125000003226 pyrazolyl group Chemical group 0.000 claims 2
125000002098 pyridazinyl group Chemical group 0.000 claims 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
VKZXJUBADCMWAN-LRDDRELGSA-N (2S,3S)-1-cyano-N-(6-ethynylisoquinolin-3-yl)-2-methylpyrrolidine-3-carboxamide Chemical compound C(#N)N1[C@H]([C@H](CC1)C(=O)NC=1N=CC2=CC=C(C=C2C=1)C#C)C VKZXJUBADCMWAN-LRDDRELGSA-N 0.000 claims 1
GTXJCUXQYGCWEV-GWCFXTLKSA-N (2S,3S)-1-cyano-N-[5-(4-fluorophenyl)-1,3-thiazol-2-yl]-2-methylpyrrolidine-3-carboxamide Chemical compound C(#N)N1[C@H]([C@H](CC1)C(=O)NC=1SC(=CN=1)C1=CC=C(C=C1)F)C GTXJCUXQYGCWEV-GWCFXTLKSA-N 0.000 claims 1
CGNVTUFYDMIHFF-GUTXKFCHSA-N (2S,3S)-1-cyano-N-[5-[[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]-2-methylpyrrolidine-3-carboxamide Chemical compound C(#N)N1[C@H]([C@H](CC1)C(=O)NC=1SC(=CN=1)CN1[C@H](CCC1)COC)C CGNVTUFYDMIHFF-GUTXKFCHSA-N 0.000 claims 1
JKIARXUZVJRKQO-FZMZJTMJSA-N (2S,3S)-1-cyano-N-[6-(3,5-dimethyl-1,2-oxazol-4-yl)-1,3-benzothiazol-2-yl]-2-methylpyrrolidine-3-carboxamide Chemical compound C(#N)N1[C@H]([C@H](CC1)C(=O)NC=1SC2=C(N=1)C=CC(=C2)C=1C(=NOC=1C)C)C JKIARXUZVJRKQO-FZMZJTMJSA-N 0.000 claims 1
TXNQBQNMJMUZGZ-AWEZNQCLSA-N (3S)-1-cyano-N-[1-[4-(1H-pyrazol-4-yl)phenyl]imidazol-4-yl]pyrrolidine-3-carboxamide Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N TXNQBQNMJMUZGZ-AWEZNQCLSA-N 0.000 claims 1
FJOMDXXHHMDCQY-QMMMGPOBSA-N (3S)-N-(4-bromo-1,3-benzothiazol-2-yl)-1-cyanopyrrolidine-3-carboxamide Chemical compound BrC1=CC=CC2=C1N=C(S2)NC(=O)[C@@H]1CN(CC1)C#N FJOMDXXHHMDCQY-QMMMGPOBSA-N 0.000 claims 1
JHYOQDQDNAQVDZ-NSHDSACASA-N (3S)-N-(4-tert-butylpyridin-2-yl)-1-cyanopyrrolidine-3-carboxamide Chemical compound C(C)(C)(C)C1=CC(=NC=C1)NC(=O)[C@@H]1CN(CC1)C#N JHYOQDQDNAQVDZ-NSHDSACASA-N 0.000 claims 1
SHHFNIBGHJMBCY-JTQLQIEISA-N (3S)-N-(5-acetyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl)-1-cyanopyrrolidine-3-carboxamide Chemical compound C(C)(=O)N1CC2=C(CC1)N=C(S2)NC(=O)[C@@H]1CN(CC1)C#N SHHFNIBGHJMBCY-JTQLQIEISA-N 0.000 claims 1
UCDHMEQBKFBKBF-AWEZNQCLSA-N (3S)-N-(5-benzoyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl)-1-cyanopyrrolidine-3-carboxamide Chemical compound C(C1=CC=CC=C1)(=O)N1CC2=C(CC1)N=C(S2)NC(=O)[C@@H]1CN(CC1)C#N UCDHMEQBKFBKBF-AWEZNQCLSA-N 0.000 claims 1
YJJIKVGCLBVIFP-ZDUSSCGKSA-N (3S)-N-(5-benzyl-1,3-thiazol-2-yl)-1-cyanopyrrolidine-3-carboxamide Chemical compound C(C1=CC=CC=C1)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N YJJIKVGCLBVIFP-ZDUSSCGKSA-N 0.000 claims 1
HQXYTMRMWGNBLL-HNNXBMFYSA-N (3S)-N-(5-benzyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl)-1-cyanopyrrolidine-3-carboxamide Chemical compound C(C1=CC=CC=C1)N1CC2=C(CC1)N=C(S2)NC(=O)[C@@H]1CN(CC1)C#N HQXYTMRMWGNBLL-HNNXBMFYSA-N 0.000 claims 1
DXABEWCFOWXFGL-ZDUSSCGKSA-N (3S)-N-[4-(2-aminopyridin-4-yl)pyridin-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound NC1=NC=CC(=C1)C1=CC(=NC=C1)NC(=O)[C@@H]1CN(CC1)C#N DXABEWCFOWXFGL-ZDUSSCGKSA-N 0.000 claims 1
XZLRSLARHIWBKL-JTQLQIEISA-N (3S)-N-[5-(3-carbamoyl-4-chlorophenyl)-1,3-thiazol-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound C(N)(=O)C=1C=C(C=CC=1Cl)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N XZLRSLARHIWBKL-JTQLQIEISA-N 0.000 claims 1
XRKVGRUFIYENQY-JTQLQIEISA-N (3S)-N-[5-(3-carbamoyl-4-fluorophenyl)-1,3-thiazol-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound C(N)(=O)C=1C=C(C=CC=1F)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N XRKVGRUFIYENQY-JTQLQIEISA-N 0.000 claims 1
OSAZFRVABHWONK-LBPRGKRZSA-N (3S)-N-[5-(3-carbamoylphenyl)-1,3-thiazol-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound C(N)(=O)C=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N OSAZFRVABHWONK-LBPRGKRZSA-N 0.000 claims 1
ZUZKXUSKSSNGKB-NSHDSACASA-N (3S)-N-[5-[4-chloro-3-(methylcarbamoyl)phenyl]-1,3-thiazol-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N)C(NC)=O ZUZKXUSKSSNGKB-NSHDSACASA-N 0.000 claims 1
RJSBETXOGALYTL-ZDUSSCGKSA-N (3S)-N-[5-[4-chloro-3-(prop-2-ynylcarbamoyl)phenyl]-1,3-thiazol-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N)C(NCC#C)=O RJSBETXOGALYTL-ZDUSSCGKSA-N 0.000 claims 1
ORWZSTGSAIMIEN-LBPRGKRZSA-N (3S)-N-[6-(3-chlorophenyl)pyrimidin-4-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound ClC=1C=C(C=CC=1)C1=CC(=NC=N1)NC(=O)[C@@H]1CN(CC1)C#N ORWZSTGSAIMIEN-LBPRGKRZSA-N 0.000 claims 1
PRENCFYNJJFJFB-ZYHUDNBSSA-N (3S,4S)-N-[5-(2-chlorophenyl)-1,3-thiazol-2-yl]-1-cyano-4-methylpyrrolidine-3-carboxamide Chemical compound ClC1=C(C=CC=C1)C1=CN=C(S1)NC(=O)[C@@H]1CN(C[C@H]1C)C#N PRENCFYNJJFJFB-ZYHUDNBSSA-N 0.000 claims 1
125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
CKABNPYWAWXCAM-UHFFFAOYSA-N 2-[5-[2-(acetamidomethyl)piperidin-1-yl]-1,3-thiazol-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound C(C)(=O)NCC1N(CCCC1)C1=CN=C(S1)C1N(CCC1C(=O)N)C#N CKABNPYWAWXCAM-UHFFFAOYSA-N 0.000 claims 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
208000035143 Bacterial infection Diseases 0.000 claims 1
BHVCQGUTQPZCOF-UHFFFAOYSA-N BrC1=CC2=C(N=C(S2)NC(=O)C2CN(CC2)C#N)C=C1 Chemical compound BrC1=CC2=C(N=C(S2)NC(=O)C2CN(CC2)C#N)C=C1 BHVCQGUTQPZCOF-UHFFFAOYSA-N 0.000 claims 1
AIODGJZUBQBVQM-VIFPVBQESA-N BrC1=CN2C=C(NC(=O)[C@H]3CCN(C3)C#N)N=C2C=C1 Chemical compound BrC1=CN2C=C(NC(=O)[C@H]3CCN(C3)C#N)N=C2C=C1 AIODGJZUBQBVQM-VIFPVBQESA-N 0.000 claims 1
KNRFPFHKUXXXNO-UHFFFAOYSA-N C(#N)N1C2CC2C(C1)C(=O)NC=1SC(=CN=1)C1=CC=CC=C1 Chemical compound C(#N)N1C2CC2C(C1)C(=O)NC=1SC(=CN=1)C1=CC=CC=C1 KNRFPFHKUXXXNO-UHFFFAOYSA-N 0.000 claims 1
JFIKNGYHBYVNOC-UHFFFAOYSA-N C(#N)N1CC2(CC2C1)C(=O)NC=1SC(=CN=1)C1=CC=CC=C1 Chemical compound C(#N)N1CC2(CC2C1)C(=O)NC=1SC(=CN=1)C1=CC=CC=C1 JFIKNGYHBYVNOC-UHFFFAOYSA-N 0.000 claims 1
XGMVWIXSYSMYDX-JTQLQIEISA-N C(#N)N1C[C@H](CC1)C(=O)NC=1SC(=CN=1)C1=CC=CC(=N1)C(=O)NC Chemical compound C(#N)N1C[C@H](CC1)C(=O)NC=1SC(=CN=1)C1=CC=CC(=N1)C(=O)NC XGMVWIXSYSMYDX-JTQLQIEISA-N 0.000 claims 1
JPUQCDVVQASFAY-NSHDSACASA-N C(#N)N1C[C@H](CC1)C(=O)NC=1SC(=CN=1)C1=CC=CC(=N1)C(=O)NCC Chemical compound C(#N)N1C[C@H](CC1)C(=O)NC=1SC(=CN=1)C1=CC=CC(=N1)C(=O)NCC JPUQCDVVQASFAY-NSHDSACASA-N 0.000 claims 1
MZPAENDVTMSUAQ-UHFFFAOYSA-N C(C)(C)(C)C1=CC(=NO1)NC(=O)C1CN(CC1)C#N Chemical compound C(C)(C)(C)C1=CC(=NO1)NC(=O)C1CN(CC1)C#N MZPAENDVTMSUAQ-UHFFFAOYSA-N 0.000 claims 1
RMNKYZKFYHLFNI-UHFFFAOYSA-N C(C)(C)(C)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N Chemical compound C(C)(C)(C)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N RMNKYZKFYHLFNI-UHFFFAOYSA-N 0.000 claims 1
APJJMSNFLIUIQO-UHFFFAOYSA-N C(C)(C)(C)C1=NNC(=C1)NC(=O)C1CN(CC1)C#N Chemical compound C(C)(C)(C)C1=NNC(=C1)NC(=O)C1CN(CC1)C#N APJJMSNFLIUIQO-UHFFFAOYSA-N 0.000 claims 1
RNQSARIBHGIFPY-BHWOMJMDSA-N C(C1=CC=CC=C1)(=O)N1CC(CC1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound C(C1=CC=CC=C1)(=O)N1CC(CC1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N RNQSARIBHGIFPY-BHWOMJMDSA-N 0.000 claims 1
DAVSYRJECGSSFM-ZENAZSQFSA-N C(C1=CC=CC=C1)(=O)N1CC(CCC1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound C(C1=CC=CC=C1)(=O)N1CC(CCC1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N DAVSYRJECGSSFM-ZENAZSQFSA-N 0.000 claims 1
HLRMDCYOJNVDDM-HNNXBMFYSA-N C(C1=CC=CC=C1)N1C(=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N)C Chemical compound C(C1=CC=CC=C1)N1C(=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N)C HLRMDCYOJNVDDM-HNNXBMFYSA-N 0.000 claims 1
SZHUYGLQCAIUAC-AWEZNQCLSA-N C(C1=CC=CC=C1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound C(C1=CC=CC=C1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N SZHUYGLQCAIUAC-AWEZNQCLSA-N 0.000 claims 1
IGWWDQJUTZXMQM-ZFWWWQNUSA-N C(C1=CC=CC=C1)N1C=NC(=C1)NC(=O)[C@@H]1[C@@H](N(CC1)C#N)C Chemical compound C(C1=CC=CC=C1)N1C=NC(=C1)NC(=O)[C@@H]1[C@@H](N(CC1)C#N)C IGWWDQJUTZXMQM-ZFWWWQNUSA-N 0.000 claims 1
JHPXJPVOGLVUBG-OYKVQYDMSA-N C(C1=CC=CC=C1)N1CC(CCC1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound C(C1=CC=CC=C1)N1CC(CCC1)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N JHPXJPVOGLVUBG-OYKVQYDMSA-N 0.000 claims 1
LDKKEXNGYYNAJO-UHFFFAOYSA-N C(C1=CC=CC=C1)N1N=CC2=CC(=CC=C12)NC(=O)C1CN(CC1)C#N Chemical compound C(C1=CC=CC=C1)N1N=CC2=CC(=CC=C12)NC(=O)C1CN(CC1)C#N LDKKEXNGYYNAJO-UHFFFAOYSA-N 0.000 claims 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
IXUZUKBFLYSJPC-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N Chemical compound ClC1=C(C=CC=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N IXUZUKBFLYSJPC-UHFFFAOYSA-N 0.000 claims 1
NMWGVSWDQQMURY-QWRGUYRKSA-N ClC1=C(C=CC=C1)C1=CN=C(S1)NC(=O)[C@@H]1[C@@H](N(CC1)C#N)C Chemical compound ClC1=C(C=CC=C1)C1=CN=C(S1)NC(=O)[C@@H]1[C@@H](N(CC1)C#N)C NMWGVSWDQQMURY-QWRGUYRKSA-N 0.000 claims 1
KEQPVMHYALYIAB-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N Chemical compound ClC1=CC=C(C=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N KEQPVMHYALYIAB-UHFFFAOYSA-N 0.000 claims 1
OIZMSGKXLFALNT-UHFFFAOYSA-N ClC=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N Chemical compound ClC=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N OIZMSGKXLFALNT-UHFFFAOYSA-N 0.000 claims 1
FWSCYQGYDYQWMB-UHFFFAOYSA-N ClC=1C=CC(=NC=1)NC(=O)C1CN(CC1)C#N Chemical compound ClC=1C=CC(=NC=1)NC(=O)C1CN(CC1)C#N FWSCYQGYDYQWMB-UHFFFAOYSA-N 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
239000004472 Lysine Substances 0.000 claims 1
KQBFXTNXFOVUTF-UHFFFAOYSA-N N-[5-(1-methylpyrazole-3-carbonyl)-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl]pyrrolidine-3-carboxamide Chemical compound N1CC(CC1)C(=O)NC=1SC=2CN(CCC=2N=1)C(=O)C1=NN(C=C1)C KQBFXTNXFOVUTF-UHFFFAOYSA-N 0.000 claims 1
KPLJYWXHFAHRIS-UHFFFAOYSA-N N-[5-(2-acetamidophenyl)-1,3-thiazol-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound C(C)(=O)NC1=C(C=CC=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N KPLJYWXHFAHRIS-UHFFFAOYSA-N 0.000 claims 1
BGUNRWZUBLLIBG-UHFFFAOYSA-N N-[5-(4-acetamidophenyl)-1,3-thiazol-2-yl]-1-cyanopyrrolidine-3-carboxamide Chemical compound C(C)(=O)NC1=CC=C(C=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N BGUNRWZUBLLIBG-UHFFFAOYSA-N 0.000 claims 1
GRBVYZNTYUZXDE-AWEZNQCLSA-N N1(C=NC=C1)C=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1(C=NC=C1)C=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N GRBVYZNTYUZXDE-AWEZNQCLSA-N 0.000 claims 1
RFACZTBXOVRENT-UHFFFAOYSA-N N1(C=NC=C1)C=1C=CC(=NC=1)NC(=O)C1CN(CC1)C#N Chemical compound N1(C=NC=C1)C=1C=CC(=NC=1)NC(=O)C1CN(CC1)C#N RFACZTBXOVRENT-UHFFFAOYSA-N 0.000 claims 1
AFZQYUGAXSIOCW-AWEZNQCLSA-N N1(N=CC=C1)C=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1(N=CC=C1)C=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N AFZQYUGAXSIOCW-AWEZNQCLSA-N 0.000 claims 1
KMMVPJWFECGWBR-JTQLQIEISA-N N1(N=NC=C1)C1=CC2=C(N=C(S2)NC(=O)[C@@H]2CN(CC2)C#N)C=C1 Chemical compound N1(N=NC=C1)C1=CC2=C(N=C(S2)NC(=O)[C@@H]2CN(CC2)C#N)C=C1 KMMVPJWFECGWBR-JTQLQIEISA-N 0.000 claims 1
WRGYUEISZKUVFV-UHFFFAOYSA-N N1=C(C=CC=C1)C=1C=NC(=CC=1)NC(=O)C1CN(CC1)C#N Chemical compound N1=C(C=CC=C1)C=1C=NC(=CC=1)NC(=O)C1CN(CC1)C#N WRGYUEISZKUVFV-UHFFFAOYSA-N 0.000 claims 1
SWRQNVFTHWCRNS-UHFFFAOYSA-N N1=CC(=CC=C1NC(=O)C1CN(CC1)C#N)C1=CC=NC=C1 Chemical compound N1=CC(=CC=C1NC(=O)C1CN(CC1)C#N)C1=CC=NC=C1 SWRQNVFTHWCRNS-UHFFFAOYSA-N 0.000 claims 1
XLCDMTPISPOBCL-UHFFFAOYSA-N N1=CC(=CC=C1NC(=O)C1CN(CC1)C#N)C=1C=NC=CC=1 Chemical compound N1=CC(=CC=C1NC(=O)C1CN(CC1)C#N)C=1C=NC=CC=1 XLCDMTPISPOBCL-UHFFFAOYSA-N 0.000 claims 1
HHJGYZXSCNPNHK-UHFFFAOYSA-N N1C(=NC2=C1C=CC=C2)NC(=O)C1CN(CC1)C#N Chemical compound N1C(=NC2=C1C=CC=C2)NC(=O)C1CN(CC1)C#N HHJGYZXSCNPNHK-UHFFFAOYSA-N 0.000 claims 1
VNOHGQXXFUTKOA-NSHDSACASA-N N1N=CC(=C1)C1=CC(=NC=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC(=C1)C1=CC(=NC=C1)NC(=O)[C@@H]1CN(CC1)C#N VNOHGQXXFUTKOA-NSHDSACASA-N 0.000 claims 1
UBINMZDMIAMZHD-NSHDSACASA-N N1N=CC(=C1)C1=CC2=C(N=C(S2)NC(=O)[C@@H]2CN(CC2)C#N)C=C1 Chemical compound N1N=CC(=C1)C1=CC2=C(N=C(S2)NC(=O)[C@@H]2CN(CC2)C#N)C=C1 UBINMZDMIAMZHD-NSHDSACASA-N 0.000 claims 1
HCYHSQGCEBEMPP-SJCJKPOMSA-N N1N=CC(=C1)C=1C=C2C=C(N=CC2=CC=1)NC(=O)[C@@H]1[C@@H](N(CC1)C#N)C Chemical compound N1N=CC(=C1)C=1C=C2C=C(N=CC2=CC=1)NC(=O)[C@@H]1[C@@H](N(CC1)C#N)C HCYHSQGCEBEMPP-SJCJKPOMSA-N 0.000 claims 1
GXVDCZIBJCUNID-ZDUSSCGKSA-N N1N=CC2=C(C=CC=C12)C1=CC(=NC=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC2=C(C=CC=C12)C1=CC(=NC=C1)NC(=O)[C@@H]1CN(CC1)C#N GXVDCZIBJCUNID-ZDUSSCGKSA-N 0.000 claims 1
BUOYQMJGANGRHQ-JTQLQIEISA-N N1N=CC2=C(C=CC=C12)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC2=C(C=CC=C12)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N BUOYQMJGANGRHQ-JTQLQIEISA-N 0.000 claims 1
WAJLKLBPLSPUDX-NSHDSACASA-N N1N=CC2=C(C=CC=C12)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC2=C(C=CC=C12)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N WAJLKLBPLSPUDX-NSHDSACASA-N 0.000 claims 1
WDSJKVGUQVHPHS-NSHDSACASA-N N1N=CC2=CC(=CC=C12)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC2=CC(=CC=C12)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N WDSJKVGUQVHPHS-NSHDSACASA-N 0.000 claims 1
JUMWSSUIRWBRPN-NSHDSACASA-N N1N=CC2=CC(=CC=C12)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC2=CC(=CC=C12)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N JUMWSSUIRWBRPN-NSHDSACASA-N 0.000 claims 1
NBQHSIPEPBNLHZ-LBPRGKRZSA-N N1N=CC2=CC=C(C=C12)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC2=CC=C(C=C12)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N NBQHSIPEPBNLHZ-LBPRGKRZSA-N 0.000 claims 1
JIYXWYLKKGJVNC-LBPRGKRZSA-N N1N=CC2=CC=C(C=C12)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC2=CC=C(C=C12)N1C=NC(=C1)NC(=O)[C@@H]1CN(CC1)C#N JIYXWYLKKGJVNC-LBPRGKRZSA-N 0.000 claims 1
HISRUPVUENHTJW-NSHDSACASA-N N1N=CC2=CC=CC(=C12)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N Chemical compound N1N=CC2=CC=CC(=C12)C1=CN=C(S1)NC(=O)[C@@H]1CN(CC1)C#N HISRUPVUENHTJW-NSHDSACASA-N 0.000 claims 1
JBEDCWHDJODVBQ-JTQLQIEISA-N N=1N(N=CC=1)C1=CC2=C(N=C(S2)NC(=O)[C@@H]2CN(CC2)C#N)C=C1 Chemical compound N=1N(N=CC=1)C1=CC2=C(N=C(S2)NC(=O)[C@@H]2CN(CC2)C#N)C=C1 JBEDCWHDJODVBQ-JTQLQIEISA-N 0.000 claims 1
ONBRCHSLMPPOFE-UHFFFAOYSA-N NC1=C(C=CC=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N Chemical compound NC1=C(C=CC=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N ONBRCHSLMPPOFE-UHFFFAOYSA-N 0.000 claims 1
HSPHUSIHVQPOGW-UHFFFAOYSA-N NC1=CC=C(C=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N Chemical compound NC1=CC=C(C=C1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N HSPHUSIHVQPOGW-UHFFFAOYSA-N 0.000 claims 1
JNVKZQDEAIDYCB-UHFFFAOYSA-N NC=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N Chemical compound NC=1C=C(C=CC=1)C1=CN=C(S1)NC(=O)C1CN(CC1)C#N JNVKZQDEAIDYCB-UHFFFAOYSA-N 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
SATJOCRUOKYVHG-INIZCTEOSA-N O=C(NC1=NN2CCN(CC3=CC=CC=C3)CC2=C1)[C@H]1CCN(C1)C#N Chemical compound O=C(NC1=NN2CCN(CC3=CC=CC=C3)CC2=C1)[C@H]1CCN(C1)C#N SATJOCRUOKYVHG-INIZCTEOSA-N 0.000 claims 1
PKCWBSHISURXPU-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)NC(=O)C1CN(CC1)C#N Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)C1CN(CC1)C#N PKCWBSHISURXPU-UHFFFAOYSA-N 0.000 claims 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
208000036142 Viral infection Diseases 0.000 claims 1
125000003342 alkenyl group Chemical group 0.000 claims 1
125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 claims 1
208000022362 bacterial infectious disease Diseases 0.000 claims 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
238000006243 chemical reaction Methods 0.000 claims 1
125000001309 chloro group Chemical group Cl* 0.000 claims 1
125000004122 cyclic group Chemical group 0.000 claims 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
125000005959 diazepanyl group Chemical group 0.000 claims 1
125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims 1
229910052731 fluorine Inorganic materials 0.000 claims 1
125000005842 heteroatom Chemical group 0.000 claims 1
125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
208000030159 metabolic disease Diseases 0.000 claims 1
238000000034 method Methods 0.000 claims 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
125000002950 monocyclic group Chemical group 0.000 claims 1
125000002757 morpholinyl group Chemical group 0.000 claims 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
229910052757 nitrogen Inorganic materials 0.000 claims 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
125000001715 oxadiazolyl group Chemical group 0.000 claims 1
125000002971 oxazolyl group Chemical group 0.000 claims 1
125000004430 oxygen atom Chemical group O* 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
125000004193 piperazinyl group Chemical group 0.000 claims 1
125000003386 piperidinyl group Chemical group 0.000 claims 1
125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
125000003003 spiro group Chemical group 0.000 claims 1
229910052717 sulfur Chemical group 0.000 claims 1
239000011593 sulfur Chemical group 0.000 claims 1
238000003419 tautomerization reaction Methods 0.000 claims 1
125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
125000001113 thiadiazolyl group Chemical group 0.000 claims 1
125000000335 thiazolyl group Chemical group 0.000 claims 1
125000001425 triazolyl group Chemical group 0.000 claims 1
230000003612 virological effect Effects 0.000 claims 1

JP2017514705A 2014-09-23 2015-09-22 新規化合物 Active JP6549703B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2019119342A JP6959299B2 (ja)	2014-09-23	2019-06-27	新規化合物

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1416754.8A GB201416754D0 (en)	2014-09-23	2014-09-23	Novel compounds
GB1416754.8		2014-09-23
PCT/GB2015/052729 WO2016046530A1 (en)	2014-09-23	2015-09-22	Novel compounds

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2019119342A Division JP6959299B2 (ja)	2014-09-23	2019-06-27	新規化合物

Publications (3)

Publication Number	Publication Date
JP2017530960A JP2017530960A (ja)	2017-10-19
JP2017530960A5 true JP2017530960A5 (2)	2018-11-08
JP6549703B2 JP6549703B2 (ja)	2019-07-24

Family

ID=51869322

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2017514705A Active JP6549703B2 (ja)	2014-09-23	2015-09-22	新規化合物
JP2019119342A Active JP6959299B2 (ja)	2014-09-23	2019-06-27	新規化合物
JP2021092454A Active JP7261264B2 (ja)	2014-09-23	2021-06-01	新規化合物

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2019119342A Active JP6959299B2 (ja)	2014-09-23	2019-06-27	新規化合物
JP2021092454A Active JP7261264B2 (ja)	2014-09-23	2021-06-01	新規化合物

Country Status (24)

Country	Link
US (5)	US9926307B2 (2)
EP (2)	EP3828179A1 (2)
JP (3)	JP6549703B2 (2)
KR (1)	KR102493967B1 (2)
CN (2)	CN111592534B (2)
AU (1)	AU2015323572B2 (2)
CA (1)	CA2958262C (2)
CY (1)	CY1122983T1 (2)
DK (1)	DK3197883T3 (2)
ES (1)	ES2798473T3 (2)
GB (1)	GB201416754D0 (2)
HR (1)	HRP20200962T1 (2)
HU (1)	HUE050732T2 (2)
IL (1)	IL250345B (2)
LT (1)	LT3197883T (2)
MX (1)	MX2017003358A (2)
PL (1)	PL3197883T3 (2)
PT (1)	PT3197883T (2)
RS (1)	RS60468B1 (2)
RU (1)	RU2691389C2 (2)
SG (1)	SG11201700847YA (2)
SI (1)	SI3197883T1 (2)
SM (1)	SMT202000323T1 (2)
WO (1)	WO2016046530A1 (2)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110526912B (zh)	2014-06-19	2023-02-14	武田药品工业株式会社	用于激酶抑制的杂芳基化合物
GB201416754D0 (en) *	2014-09-23	2014-11-05	Mission Therapeutics Ltd	Novel compounds
MX373656B (es) *	2015-03-30	2020-04-02	Mission Therapeutics Ltd	Compuestos de 1-ciano-pirrolidina como inhibidores de las enzimas desubiquitinantes, como la hidrolasa 30 de la c-terminal de la ubiquitina (usp30), y el uso de los mismos en el tratamiento de condiciones de disfunción mitocondrial y tratamiento de cancér.
CN107922386B (zh) *	2015-06-22	2021-04-02	大日本住友制药株式会社	1,4-二取代的咪唑衍生物
US10669234B2 (en)	2015-07-14	2020-06-02	Mission Therapeutics Limited	Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) *	2015-11-30	2016-01-13	Mission Therapeutics Ltd	Novel compounds
GB201522267D0 (en)	2015-12-17	2016-02-03	Mission Therapeutics Ltd	Novel compounds
GB201522768D0 (en) *	2015-12-23	2016-02-03	Mission Therapeutics Ltd	Novel compounds
GB201602854D0 (en) *	2016-02-18	2016-04-06	Mission Therapeutics Ltd	Novel compounds
GB201603779D0 (en) *	2016-03-04	2016-04-20	Mission Therapeutics Ltd	Novel compounds
GB201604647D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
GB201604638D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
JP6959252B2 (ja)	2016-03-24	2021-11-02	ミッションセラピューティクスリミティド	Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
WO2017184751A1 (en) *	2016-04-20	2017-10-26	Arizona Board Of Regents On Behalf Of The University Of Arizona	Compositions and methods for treating and preventing hypertension
AR108326A1 (es)	2016-04-27	2018-08-08	Samumed Llc	Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es)	2016-04-27	2018-08-08	Samumed Llc	Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
ES2850349T3 (es)	2016-09-27	2021-08-27	Mission Therapeutics Ltd	Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en)	2016-09-29	2016-11-16	Mission Therapeutics Limited	Novel compounds
GB201616627D0 (en) *	2016-09-30	2016-11-16	Mission Therapeutics Limited	Novel compounds
TWI771327B (zh)	2016-10-05	2022-07-21	英商使命醫療公司	新穎化合物
WO2018148863A1 (zh) *	2017-02-14	2018-08-23	华东理工大学	N-(5-吗啉代噻唑-2-基)甲酰胺类化合物及其制备方法和用途
CN110944637A (zh) *	2017-05-10	2020-03-31	库特克希米公司	氨基吡啶化合物及其制备方法和使用方法
GB201708652D0 (en) *	2017-05-31	2017-07-12	Mission Therapeutics Ltd	Novel compounds and uses
AR112027A1 (es)	2017-06-15	2019-09-11	Biocryst Pharm Inc	Inhibidores de alk 2 quinasa que contienen imidazol
JP7208931B2 (ja) *	2017-06-20	2023-01-19	ミッションセラピューティクスリミティド	Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
RS64035B1 (sr) *	2017-08-01	2023-04-28	Merck Patent Gmbh	Derivati tiazolopiridina kao antagonisti receptora adenozina
CN107445981B (zh) *	2017-08-25	2018-06-22	牡丹江医学院	一种用于防治宫颈炎的活性化合物
BR112020003725A2 (pt) *	2017-10-06	2020-11-03	Forma Therapeutics, Inc.	inibição da peptidase 30 específica de ubiquitina
US10604514B2 (en) *	2017-10-19	2020-03-31	Samumed, Llc	6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en)	2017-10-27	2019-09-17	Samumed, Llc	6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10653688B2 (en)	2017-10-27	2020-05-19	Samumed, Llc	6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10703748B2 (en)	2017-10-31	2020-07-07	Samumed, Llc	Diazanaphthalen-3-yl carboxamides and preparation and use thereof
AR114422A1 (es)	2018-03-30	2020-09-02	Syngenta Participations Ag	Compuestos herbicidas
US12084431B2 (en)	2018-05-14	2024-09-10	Takeda Pharmaceutical Company Limited	Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
JP7449242B2 (ja)	2018-05-17	2024-03-13	フォーマセラピューティクス，インコーポレイテッド	ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
CN112601584A (zh)	2018-07-24	2021-04-02	豪夫迈·罗氏有限公司	异喹啉化合物及其用途
EP3833441A1 (en)	2018-08-09	2021-06-16	Valo Early Discovery, Inc.	Inhibiting deubiquitinase usp25 and usp28
JP7434285B2 (ja) *	2018-08-14	2024-02-20	アムジエン・インコーポレーテツド	Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
TW202024053A (zh)	2018-10-02	2020-07-01	美商建南德克公司	異喹啉化合物及其用途
US11612606B2 (en)	2018-10-03	2023-03-28	Genentech, Inc.	8-aminoisoquinoline compounds and uses thereof
LT3860989T (lt)	2018-10-05	2023-06-12	Forma Therapeutics, Inc.	Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
AR117189A1 (es)	2018-11-02	2021-07-21	Aicuris Gmbh & Co Kg	Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
UY38435A (es)	2018-11-02	2020-05-29	Aicuris Gmbh & Co Kg	Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
CN120698983A (zh)	2018-12-20	2025-09-26	C4医药公司	靶向蛋白降解
GB201905371D0 (en)	2019-04-16	2019-05-29	Mission Therapeutics Ltd	Novel compounds
GB201905375D0 (en)	2019-04-16	2019-05-29	Mission Therapeutics Ltd	Novel compounds
WO2020256432A1 (ko) *	2019-06-19	2020-12-24	주식회사 엘지화학	인돌 또는 인다졸 화합물의 제조방법
GB201912674D0 (en) *	2019-09-04	2019-10-16	Mission Therapeutics Ltd	Novel compounds
CN114845709B (zh)	2019-11-05	2024-10-01	德米拉公司	用于治疗炎性病症的mrgprx2拮抗剂
WO2021204856A1 (en)	2020-04-08	2021-10-14	Mission Therapeutics Limited	N-cyanopyrrolidines with activity as usp30 inhibitors
WO2021236717A1 (en)	2020-05-20	2021-11-25	Senda Biosciences, Inc.	Fused imidazole derivatives as ahr antagonists
IL298526A (en) *	2020-05-28	2023-01-01	Mission Therapeutics Ltd	N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
WO2021242955A1 (en) *	2020-05-28	2021-12-02	Senda Biosciences, Inc.	Fused azole heterocycles as ahr antagonists
BR112022019722A2 (pt) *	2020-06-04	2022-12-20	Mission Therapeutics Ltd	N-cianopirrolidinas com atividade como inibidores de usp30
DK4161929T3 (da)	2020-06-08	2025-08-18	Mission Therapeutics Ltd	1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose
GB202016800D0 (en)	2020-10-22	2020-12-09	Mission Therapeutics Ltd	Novel compounds
AR125588A1 (es) *	2021-03-04	2023-08-02	Lilly Co Eli	Compuestos inhibidores de fgfr3
WO2023009982A1 (en) *	2021-07-26	2023-02-02	Dana-Farber Cancer Institute, Inc.	Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
US20250034122A1 (en)	2021-12-01	2025-01-30	Mission Therapeutics Limited	Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
KR20240133695A (ko) *	2021-12-10	2024-09-04	프로테나 바이오사이언시즈 리미티드	Dyrk1a 억제제로서의 헤테로시클릭 화합물
AU2024301960A1 (en) *	2023-06-14	2026-01-22	Prothena Biosciences Limited	Bicyclic heteroaromatic compounds for treating neurological disorders
GB202408928D0 (en)	2024-06-21	2024-08-07	Mission Therapeutics Ltd	Novel compounds
GB202411060D0 (en)	2024-07-29	2024-09-11	Mission Therapeutics Ltd	Novel compounds
CN119528901A (zh) *	2024-11-05	2025-02-28	上海市同济医院	噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5665754A (en)	1993-09-20	1997-09-09	Glaxo Wellcome Inc.	Substituted pyrrolidines
EP1072263A4 (en)	1998-03-26	2004-03-31	Japan Tobacco Inc	AMID DERIVATIVES AND NOCICEPTINANT AGONISTS
WO2001077073A1 (en) *	2000-04-06	2001-10-18	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
US7087761B2 (en)	2003-01-07	2006-08-08	Hoffmann-La Roche Inc.	Cyclization process for substituted benzothiazole derivatives
EP1737459B1 (en)	2004-03-19	2009-08-05	Warner-Lambert Company LLC	Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
WO2007063934A1 (ja)	2005-12-02	2007-06-07	Mitsubishi Tanabe Pharma Corporation	脂環式複素環化合物
TWI332501B (en) *	2006-07-14	2010-11-01	Lg Life Sciences Ltd	Melanocortin receptor agonists
WO2010052222A1 (en)	2008-11-07	2010-05-14	Evotec Neurosciences Gmbh	(dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
JP5743897B2 (ja)	2008-11-20	2015-07-01	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	化合物
EP2619184B1 (en)	2010-09-24	2018-05-23	The Regents of the University of Michigan	Deubiquitinase inhibitors and methods for use of the same
WO2012174312A2 (en)	2011-06-15	2012-12-20	Glaxosmithkline Llc	Benzimidazole derivatives as antiviral agents
PT2780326T (pt) *	2011-10-19	2019-03-04	Vivolux Ab	Método para inibição da atividade da desubiquitinação
CA2879454A1 (en)	2012-07-19	2014-01-23	Drexel University	Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
US9464311B2 (en)	2013-05-02	2016-10-11	E3X Bio, Inc.	Method for identifying modulators of ubiquitin ligases
GB201416754D0 (en) *	2014-09-23	2014-11-05	Mission Therapeutics Ltd	Novel compounds
MX373656B (es)	2015-03-30	2020-04-02	Mission Therapeutics Ltd	Compuestos de 1-ciano-pirrolidina como inhibidores de las enzimas desubiquitinantes, como la hidrolasa 30 de la c-terminal de la ubiquitina (usp30), y el uso de los mismos en el tratamiento de condiciones de disfunción mitocondrial y tratamiento de cancér.
US10669234B2 (en)	2015-07-14	2020-06-02	Mission Therapeutics Limited	Cyanopyrrolidines as dub inhibitors for the treatment of cancer

2014
- 2014-09-23 GB GBGB1416754.8A patent/GB201416754D0/en not_active Ceased
2015
- 2015-09-22 AU AU2015323572A patent/AU2015323572B2/en active Active
- 2015-09-22 CA CA2958262A patent/CA2958262C/en active Active
- 2015-09-22 SM SM20200323T patent/SMT202000323T1/it unknown
- 2015-09-22 US US15/513,125 patent/US9926307B2/en active Active
- 2015-09-22 CN CN202010193668.8A patent/CN111592534B/zh active Active
- 2015-09-22 DK DK15774652.0T patent/DK3197883T3/da active
- 2015-09-22 MX MX2017003358A patent/MX2017003358A/es active IP Right Grant
- 2015-09-22 PL PL15774652T patent/PL3197883T3/pl unknown
- 2015-09-22 RU RU2017105296A patent/RU2691389C2/ru active
- 2015-09-22 RS RS20200675A patent/RS60468B1/sr unknown
- 2015-09-22 ES ES15774652T patent/ES2798473T3/es active Active
- 2015-09-22 HU HUE15774652A patent/HUE050732T2/hu unknown
- 2015-09-22 LT LTEP15774652.0T patent/LT3197883T/lt unknown
- 2015-09-22 SI SI201531254T patent/SI3197883T1/sl unknown
- 2015-09-22 EP EP20162784.1A patent/EP3828179A1/en active Pending
- 2015-09-22 SG SG11201700847YA patent/SG11201700847YA/en unknown
- 2015-09-22 HR HRP20200962TT patent/HRP20200962T1/hr unknown
- 2015-09-22 KR KR1020177009125A patent/KR102493967B1/ko active Active
- 2015-09-22 JP JP2017514705A patent/JP6549703B2/ja active Active
- 2015-09-22 WO PCT/GB2015/052729 patent/WO2016046530A1/en not_active Ceased
- 2015-09-22 EP EP15774652.0A patent/EP3197883B1/en active Active
- 2015-09-22 PT PT157746520T patent/PT3197883T/pt unknown
- 2015-09-22 CN CN201580051365.XA patent/CN107001339B/zh active Active
2017
- 2017-01-30 IL IL250345A patent/IL250345B/en active IP Right Grant
2018
- 2018-02-12 US US15/894,025 patent/US10392380B2/en active Active
2019
- 2019-06-21 US US16/448,066 patent/US10774078B2/en active Active
- 2019-06-27 JP JP2019119342A patent/JP6959299B2/ja active Active
2020
- 2020-06-11 CY CY20201100536T patent/CY1122983T1/el unknown
- 2020-08-11 US US16/990,150 patent/US11472798B2/en active Active
2021
- 2021-06-01 JP JP2021092454A patent/JP7261264B2/ja active Active
2022
- 2022-09-01 US US17/901,390 patent/US11993595B2/en active Active

Publication	Publication Date	Title
JP2017530960A5 (2)	2018-11-08
RU2017105296A (ru)	2018-10-24	Новые соединения
JP2020514267A5 (2)	2021-02-04
AU2011344001B2 (en)	2016-06-30	Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
KR102485100B1 (ko)	2023-01-04	치환된 우레아 유도체 및 이의 약제학적 용도
US12281122B1 (en)	2025-04-22	PI3K inhibitors
US20200172546A1 (en)	2020-06-04	Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
RU2016140338A (ru)	2018-04-19	Азаспиро производные в качестве антагонистов trpm8
RU2018123779A (ru)	2020-01-17	Новые соединения
JP2018510183A5 (2)	2019-05-09
JP2016500073A5 (2)	2016-12-28
RU2017134901A (ru)	2019-04-30	Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
JP2018500376A5 (2)	2019-01-31
EP2594270A2 (en)	2013-05-22	The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
RU2015129538A (ru)	2017-01-26	Замещенные имидазопиридины в качестве ингибиторов hdm2
JP2016523911A5 (2)	2017-08-03
JP2013523884A5 (2)	2014-05-22
CN111868037B (zh)	2023-10-13	作为crhr2拮抗剂的稠合环状脲衍生物
KR20150002573A (ko)	2015-01-07	벤조티아졸-6-일 아세트산 유도체 및 ｈｉｖ 감염을 치료하기 위한 이의 용도
TW201822764A (zh)	2018-07-01	Syk抑制劑
KR20250021398A (ko)	2025-02-12	Kif18a 저해용 화합물
JP2023551290A (ja)	2023-12-07	ピロリジン誘導体及び使用方法
JPWO2019198692A5 (2)	2023-05-19
RU2020134947A (ru)	2022-05-12	Производные конденсированной циклической мочевины в антагонист crhr2
WO2026042050A1 (en)	2026-02-26	Novel compounds and uses thereof